Oxytocin in Opiate Dependence: A Pilot Study of the Effects of Intranasal Oxytocin on Emotional Processes and Stress Responses in Patients With Opiate Dependence

Overview

Opiate dependence is a serious problem, and oxytocin has many properties which make it attractive as a treatment for this type of substance dependence. This experiment will test the effects of oxytocin on a variety of brain-based processes in patients with opiate dependence. The investigators hypothesize that intranasal oxytocin in these conditions will enhance emotional processing and will have beneficial effects on stress responses in opiate-dependent patients.

Full Title of Study: “Oxytocin in Opiate Dependence: A Double-blind, Within-subjects, Placebo-controlled Pilot Study of the Effects of Intranasal Oxytocin on Emotional Processes and Stress Responses in Patients With Opiate Dependence”

Study Type

  • Study Type: Interventional
  • Study Primary Completion Date: December 2015

Interventions

  • Drug: Oxytocin

Arms, Groups and Cohorts

  • Experimental: oxytocin

Clinical Trial Outcome Measures

Primary Measures

  • Cold Pressor Task
    • Time Frame: up to 5 minutes
    • The Cold Pressure task involves placing a hand or forearm in cold water, a stimulus that produces a slowly mounting pain of mild to moderate intensity and is terminated by voluntary withdrawal of the limb. The cold pressor task has been used in many studies of pain, autonomic reactivity, and hormonal stress responses.

Participating in This Clinical Trial

Inclusion Criteria

  • adult men 18 years or older – meet DSM-IV criteria for opiate dependence, and no other active substance dependence disorder save nicotine dependence – clinically stable, and low risk for suicide as determined by principal investigator and screening questionnaire – abstinent from non-prescribed opiate use for at least two weeks from Baseline 1 and free from opiate withdrawal symptoms. If on agonist therapy, dose must be stable for 2 weeks before study visit. – must be able to use nasal spray – negative salivary drug screen, save for opiates Exclusion Criteria:

  • any active medical condition that in the opinion of the investigator will interfere with the objectives of the study – any active, severe mental illness, neurological disorder, including schizophrenia, autism, Asperger's syndrome – are unsuitable in any way to participate in this study, in the opinion of the investigator – hospitalizations due to complications of an Axis 1 disorder for the past 12 months, excluding drug or alcohol rehabilitation – any clinically significant chronic pain condition, as determined by the principal investigator – positive salivary drug screen at the time of the visit, for any substance other than opiates or another prescribed medication

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: N/A

Investigator Details

  • Lead Sponsor
    • MacDonald, Kai, M.D.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Nick Schaffner, 619-543-6999

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.